Health
Secukinumab Has High Retention Rate in Real-World Psoriatic Arthritis Study – AJMC.com Managed Markets Network
New real-world data shows 64% of patients with psoriatic arthritis who had previously been on a biologic stayed on secukinumab for the duration of the study.
A new study suggests secukinumab (Cosenytx) has a high retention rate among biologic-experienced patients with psoriatic arthritis (PsA) in real-world settings, and also produces minimal serious side effects.
The research is important because previous data on the real-world usage of the recombinant human monoclonal antibody has been scarce. The drug, which targets interleukin-17A, has been approved for the treatment of PsA since 2015 in Europe and 2016 in the United States.
A team of Greek inv…
-
Noosa News17 hours agoMan arrested after fatal shooting at Beenleigh, south of Brisbane
-
Noosa News16 hours agoQueensland Police called to Hugh Muntz Park in Beenleigh, Logan after reports of a man was shot
-
General19 hours agoSmall businesses losing thousands to fraudulent online chargeback claims
-
General18 hours agoBotched estimates reveal big aged care worker shortage